<?xml version="1.0"?>
<trials subjects="1">
  <Triall>
    <main>
      <UTRN />
      <trial_id>ChiCTR-OCC-15006663</trial_id>
      <utrn />
      <reg_name>ChiCTR</reg_name>
      <date_registration>2015-06-29</date_registration>
      <primary_sponsor>Hematologic disease center,First Affiliated Hospital of XinJiang Medical University</primary_sponsor>
      <public_title>Multicenter clinical research of related HLA-haploidentical/mismatched allogeneic non T cell-depleted in vitro peripheral blood hematopoietic stem cell transplantation for hematologic malignance</public_title>
      <acronym />
      <scientific_title>Multicenter clinical research of related HLA-haploidentical/mismatched allogeneic non T cell-depleted in vitro peripheral blood hematopoietic stem cell transplantation for hematologic malignance</scientific_title>
      <Scientific_acronym />
      <date_enrolment>2015-07-01</date_enrolment>
      <type_enrolment />
      <target_size>Case series:100;</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>http://www.chictr.org.cn/showproj.aspx?proj=11325</url>
      <study_type>Observational study</study_type>
      <study_design>Case series</study_design>
      <phase>New Treatment Measure Clinical Study</phase>
      <hc_freetext>hematologic malignance</hc_freetext>
      <i_freetext>Case series:Related HLA-haploidentical/mismatched allogeneic non T cell-depleted in vitro peripheral blood hematopoietic stem cell transplantation;</i_freetext>
      <results_actual_enrolment />
      <results_date_completed />
      <results_url_link />
      <results_summary />
      <results_date_posted />
      <results_date_first_publication />
      <results_baseline_char />
      <results_participant_flow />
      <results_adverse_events />
      <results_outcome_measures />
      <results_url_protocol />
      <results_IPD_plan />
      <results_IPD_description />
    </main>
    <contacts>
      <contact>
        <type>Scientific</type>
        <firstname>XianLin Duan</firstname>
        <middlename />
        <lastname />
        <address>8 Liyushan road, Urumuqi, Xinjiang Uygur Autonomous Region, China</address>
        <city />
        <country1 />
        <zip>830061</zip>
        <telephone>+86 18690172656</telephone>
        <email>wqw.056@163.com</email>
        <affiliation>Hematologic disease center, First Affiliated Hospital of Xinjiang Medical University</affiliation>
      </contact>
      <contact>
        <type>Public</type>
        <firstname>Ming Jiang</firstname>
        <middlename />
        <lastname />
        <address>8 Liyushan road, Urumuqi, Xinjiang Uygur Autonomous Region, China</address>
        <city />
        <country1 />
        <zip>830061</zip>
        <telephone>+86 13609910116</telephone>
        <email>jiangmingyy@126.com</email>
        <affiliation />
      </contact>
    </contacts>
    <countries>
      <country2>China</country2>
    </countries>
    <criteria>
      <inclusion_criteria>1) Age: 15 to 50 years old;
2) Confirmed diagnosis hematological malignancies, including: ALL in initial treatment (standard risk and high risk group), AML in initial treatment?except M3 (moderated and high risk group), MDS (IPSS up 3.5), recurrence of refractory ALL and AML(note: use a IPSS MDS - R scoring system);
3) HLA-matching all used high resolution genotyping and choose 2/6 or 3/6 HLA-halpltype (HLA - A, B and DRB1);
4) Patiens haven't severely organ injury of heart, lung, kidney, only mild damage to liver function (Child class A);
5) The following feasible transplantation: patients with hepatitis b virsus, hepatitis c virsus of not actively liver damage and strict monitoring viral replication in normal copy number; with TB infection of infected has been control, under continue to anti-TB treatment; patients have?fungal infection?recently of full control of infected site;
6) All volunteer signed the informed consent.</inclusion_criteria>
      <agemin>15</agemin>
      <agemax>50</agemax>
      <gender>Both</gender>
      <exclusion_criteria>1) There is difficult to control the active infection;
2) Patients have organ injury of heart, lung, kidney and severe liver damage (Child class B, C);
3) Pregnancy;
4) Mental illness;
5) Patients don't sign the informed consent.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code />
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword />
    </health_condition_keyword>
    <intervention_code>
      <i_code>;</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword />
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Acute graft versus host disease;</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Chronic   graft versus host disease;Engraftment;Overall Surviver;disease free survival;transplantation related mortality;</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name />
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id />
        <issuing_authority />
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>self-financing</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2014-12-05</approval_date>
        <contact_name />
        <contact_address />
        <contact_phone />
        <contact_email />
      </ethics_review>
    </ethics_reviews>
  </Triall>
</trials>